Compare · ILMN vs LH
ILMN vs LH
Side-by-side comparison of Illumina Inc. (ILMN) and Labcorp Holdings Inc. (LH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMN and LH operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $28.93B, about 1.3x LH ($22.61B).
- Over the past year, ILMN is up 92.7% and LH is up 11.1% - ILMN leads by 81.7 points.
- ILMN has been more active in the news (10 items in the past 4 weeks vs 6 for LH).
- Both have 25 recent analyst ratings on file.
- Company
- Illumina Inc.
- Labcorp Holdings Inc.
- Price
- $187.40-2.01%
- $272.79-1.11%
- Market cap
- $28.93B
- $22.61B
- 1M return
- +16.46%
- +2.56%
- 1Y return
- +92.74%
- +11.05%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2000
- News (4w)
- 10
- 6
- Recent ratings
- 25
- 25
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Latest ILMN
- Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
- Director Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)
- Director Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)
- Bernstein resumed coverage on Illumina with a new price target
- Chief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)
- Director Skovronsky Daniel was granted 1,674 shares (SEC Form 4)
- SEC Form 3 filed by new insider Skovronsky Daniel
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors
Latest LH
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Legal Officer Kyle Kathryn W converted options into 256 shares, covered exercise/tax liability with 73 shares and sold $26,329 worth of shares (92 units at $286.19) as part of a pre-agreed trading plan, increasing direct ownership by 2% to 3,904 units (SEC Form 4) (for withholding tax)
- EVP and President, Diagnostics Vaughn Bryan T covered exercise/tax liability with 93 shares, sold $66,968 worth of shares (234 units at $286.19) as part of a pre-agreed trading plan and converted options into 327 shares (SEC Form 4) (for withholding tax)
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp to Announce Second Quarter 2026 Financial Results on July 30, 2026
- Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test
- EVP, Chief Legal Officer Kyle Kathryn W sold $201,084 worth of shares (762 units at $263.89) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 3,813 units (SEC Form 4)
- Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
- Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits